A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
NCT02013804
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
58
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Malignancies
Interventions
DRUG:
MEDI0680 (AMP-514)
Sponsor
MedImmune LLC